Trial tests creatine with GLP-1 weight-loss therapy

Key Takeaways

• This is a trial registration, not a published results paper, so it does not show that creatine works in this setting yet.
• The study’s central idea is practical: pair creatine with resistance training during GLP-1 therapy to help preserve muscle mass.
• Muscle loss during weight loss matters because it can affect strength, function, metabolic health and long-term weight maintenance.
• Creatine monohydrate is the most-studied form of creatine, and evidence supports it for strength and lean-mass gains alongside training.
• For people on GLP-1 drugs, resistance training remains the main proven strategy to defend muscle while dieting.
• Until results are published, creatine should be viewed as a plausible add-on, not a confirmed solution to GLP-1-related muscle loss.

What the new listing actually says

The news here is not that creatine has been proven to preserve muscle during GLP-1 therapy. It has not. What is new is that a registered study on ClinicalTrials.gov is explicitly testing that idea.

According to the listing, the rationale is straightforward: GLP-1 receptor agonists are effective for weight loss, but a meaningful share of that lost weight can come from muscle mass. The study therefore combines resistance training and creatine supplementation in an effort to reduce that loss.

That matters because muscle is not cosmetic extra. During any substantial weight-loss phase, preserving lean mass can help maintain strength, physical function, training capacity and resting energy expenditure. Those factors are especially relevant for people using GLP-1 drugs over months, not just weeks.

For Creatine Canada readers, the key point is this: the trial reflects a real and increasingly important clinical question. As more people use GLP-1 medications, interest is shifting from “How much weight is lost?” to “What kind of weight is lost?” If a strategy can help patients keep more muscle while still reducing body weight, it could materially improve the quality of that weight loss.

Still, this source is a study record with a short abstract, not a full paper. It tells us what researchers plan to test and why, but not yet whether the strategy works, how well it works, or in whom it works best.

Why muscle loss on GLP-1 drugs is a real issue

GLP-1 receptor agonists can drive substantial weight loss, but weight loss is rarely pure fat loss. In most calorie-deficit settings, some lean mass is typically lost along with body fat, and that concern becomes more important as total weight loss gets larger.

For people taking GLP-1 drugs, several factors can push in that direction:

• Lower food intake, which can reduce total protein and energy availability.
• Reduced training quality if appetite suppression, nausea or fatigue make hard workouts less consistent.
• Rapid body-mass reduction, which can magnify losses in lean tissue if resistance training and protein intake are not maintained.

That does not mean GLP-1 therapy is a bad option. It means body-composition quality matters. Losing fat while holding onto more muscle is generally a better outcome than simply seeing the scale drop.

This is where creatine becomes interesting. Creatine does not replace training, and it is not a fat-loss supplement. But it can support high-intensity exercise performance and, over time, help people gain or maintain lean mass when paired with resistance training. That is why the combination in this study makes scientific sense.

If you are considering creatine while dieting, our creatine guides cover the basics, and our creatine dosage calculator can help with standard daily dosing. But the practical takeaway from this new listing is narrower: researchers are now formally studying whether creatine can help solve a specific problem created by successful GLP-1 weight loss.

How the study is designed and what we can’t know yet

Because the primary source is a trial registration rather than a journal article, the available detail is limited. The abstract tells us the intervention concept: creatine supplementation during GLP-1 receptor agonist therapy, alongside resistance training, with the goal of preventing or reducing muscle-mass loss.

What the listing does not provide in the supplied source material are the results, effect sizes, adherence data, body-composition outcomes or adverse-event findings. Without those, several important questions remain unanswered:

• How much muscle loss, if any, does the combined strategy prevent?
• Is the benefit due mainly to resistance training, creatine, or the combination?
• What population is being studied: age, sex, training status, obesity severity or medication type?
• How is muscle mass assessed: DXA, bioimpedance, imaging, or another method?
• What creatine protocol is used: loading, maintenance dose, duration and form?

Those gaps matter because trial design strongly affects interpretation. A small study may be hypothesis-generating but not definitive. A non-randomized design can be useful, but it is more vulnerable to confounding. And if body composition is measured with a method that is sensitive to fluid shifts, apparent changes in “lean mass” can be harder to interpret.

So the right framing is cautious. This is a promising research question, not a proof of concept. When published data arrive, readers should look for sample size, randomization, control conditions, body-composition methods, training supervision and whether outcomes include strength or function, not only scale weight.

What this means in practice for creatine users

For someone on a GLP-1 drug who wants to minimize muscle loss, the most evidence-based priority is still progressive resistance training. Creatine may be a sensible add-on, but it should be framed as support for training and lean-mass retention, not as a stand-alone fix.

Mainstream creatine guidance remains simple. ISSN’s position stand and broader sports-nutrition practice support creatine monohydrate as the most studied form. A common maintenance approach is 3 to 5 g per day. Some people use a loading phase of about 20 g per day split into 4 doses for 5 to 7 days, then switch to maintenance.

In a GLP-1 context, practical considerations include:

• Start with tolerability in mind: a smaller daily dose may be easier than loading if appetite or GI comfort is already an issue.
• Take it consistently: timing is less important than daily adherence.
• Pair it with training: creatine’s benefits are most meaningful when resistance exercise is regular.
• Keep protein intake in view: creatine is not a substitute for adequate dietary protein.

If you are shopping, stick with plain monohydrate from reputable manufacturers rather than proprietary blends. Our best creatine rankings, creatine brand reviews and creatine product catalog can help you compare straightforward options.

People with medical conditions, complex medication regimens or clinician-directed nutrition plans should check with their healthcare team before adding any supplement.

How this fits the existing creatine evidence

The broader evidence base makes this trial idea plausible, even though it is not yet proven in GLP-1 users. Creatine is one of the most studied sports supplements, and the strongest evidence supports benefits for high-intensity exercise capacity, strength gains and increases in lean mass over time, especially when combined with resistance training.

That distinction is important. Existing creatine research does not automatically prove that creatine will prevent muscle loss during pharmacologic weight reduction. Different populations, different energy intakes and different physiological pressures can change the outcome. But there is a clear scientific rationale for testing it.

Two points from the established literature are especially relevant here:

• Creatine monohydrate is the reference form. It is the best-studied and most consistently supported option.
• Training is the foundation. Creatine tends to work best as an adjunct to resistance exercise rather than as an isolated intervention.

Readers who want background on common myths and practical questions can see this JISSN review on common questions and misconceptions about creatine. For day-to-day decision-making, the take-home is modest but useful: if muscle retention during GLP-1 therapy is the goal, creatine is scientifically credible enough to study seriously, but not yet validated enough to promise.

That is exactly where good research should begin: with a biologically plausible, practical intervention aimed at an increasingly common real-world problem.

Bottom line for people on GLP-1 therapy

This ClinicalTrials.gov listing signals an important shift in the conversation around GLP-1 medications. The question is no longer only whether these drugs reduce body weight; it is also how to preserve muscle while that weight is coming off.

Right now, the source supports three careful conclusions:

1. A study is underway to test creatine plus resistance training during GLP-1 therapy.
2. The rationale is sound because lean-mass loss during weight loss is a legitimate concern.
3. No results are available yet, so no one should claim this strategy is proven in GLP-1 users based on this source alone.

For practical readers, the hierarchy is clear. If you are using a GLP-1 drug and want to protect muscle, prioritize resistance training, maintain adequate protein intake and discuss overall nutrition with your clinician. Creatine monohydrate is a reasonable evidence-based supplement to consider, particularly if you are already lifting, but it should be viewed as an adjunct rather than the centrepiece.

When the full study is eventually published, the most important details will be whether it meaningfully improves lean-mass retention, whether it preserves strength and function, and whether the protocol is realistic for everyday patients. Until then, this is best understood as promising research in progress, not a practice-changing result.

Creatine and GLP-1 therapy: what’s known now

• 1 new registered trial — The primary source is a ClinicalTrials.gov listing, not a results paper.
• 3–5 g/day typical creatine maintenance dose — Mainstream evidence-based guidance for creatine monohydrate.
• ~20 g/day common loading protocol — Usually split into 4 doses for 5–7 days.
• 5–7 days usual loading duration — Optional; many users simply take a daily maintenance dose.

Frequently Asked Questions

Sources & Further Reading

• Kreider et al. (2017), ISSN Position Stand: Safety and Efficacy of Creatine — JISSN
• Antonio et al. (2021), Common questions and misconceptions about creatine supplementation — JISSN